Clinical trials: in China
Heart Failure
A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure
This study is open to adults aged 18 or above legal age with heart failure. People can join the study if they have heart failure symptoms and a left ventricular ejection fraction (LVEF) of 40% or more.
- Trial name
- NCT06424288
- Testing
- vicadrostat, empagliflozin
- Where
- 671 sites in United States, Argentina and 28 more
- Volunteers
- 6,712 people
- Sponsor
- Boehringer Ingelheim
Prosthetic Joint Infection (PJI)
A Phase 2b Study to Evaluate the Efficacy, Safety, and PK Profiles of TNP-2092 Administered Via IA Injection in PJI Participants
This is a Phase 2b, randomized, controlled, open-label clinical study evaluating the efficacy, safety, and local PK profiles of TNP-2092 administered via IA injection on a background of antibiotic treatment in participants with…
- Trial name
- NCT07858916
- Testing
- TNP-2092 for injection, Vancomycin Hydrochloride for Injection, Oral antibiotics
- Where
- China
- Volunteers
- 40 people
- Sponsor
- TenNor Therapeutics (Zhongshan) Limited
Liposarcoma, Prostate Cancer
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
This is a Phase 1/2A, open label, multicenter, nonrandomized, multiple dose, safety, tolerability, pharmacokinetic and pharmacodynamic study of PF-07220060 administered as a single agent and in combination with endocrine therapy.
- Conditions
- Liposarcoma, Prostate Cancer, Advanced Breast Cancer, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- CDK4i (NCT04557449)
- Testing
- PF-07220060, Letrozole, Fulvestrant
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 430 people
- Sponsor
- Pfizer
Glycogen Storage Disease Type II, Pompe Disease
Pompe Disease Registry Protocol
The Pompe Registry is a global, multicenter, international, longitudinal, observational, and voluntary program for patients with Pompe disease, designed to track the disease's natural history and outcomes in patients, both…
- Trial name
- NCT00231400
- Where
- 282 sites in United States, Argentina and 42 more
- Volunteers
- 2,000 people
- Sponsor
- Genzyme, a Sanofi Company
Pan-tumor(NSCLC, GYN Cancers, BTC and UC)
A Multicenter, Non-interventional, Descriptive Study to Assess Assay Concordance of HER2 IHC Testing in Chinese Pan-tumor Patients
This is a multicenter, non-interventional, descriptive study to retrospectively collect solid tumor samples from focused tumor types (NSCLC, GYN cancers, BTC and UC) and assess both assay concordance and interpretation…
- Trial name
- Pan HER2 (NCT07404202)
- Where
- 14 sites in China
- Volunteers
- 2,100 people
- Sponsor
- AstraZeneca
Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 or 2 Systemic Treatment Regimens
Study CL3-95031-007 (CHONQUER) is a Phase 3, international, multicenter, double-blind, randomized, placebo-controlled study of orally administered ivosidenib.
- Trial name
- CHONQUER (NCT06127407)
- Testing
- Ivosidenib 500mg
- Where
- 115 sites in United States, Australia and 15 more
- Volunteers
- 156 people
- Sponsor
- Servier Bio-Innovation LLC
Acute Ischemic Stroke
Rapid Local Ischemic Postconditioning on Stroke After Thrombectomy
The main goal of this study is to find out if a new, quick "brain rescue" procedure can help people recover better from a severe stroke caused by a large vessel occlusion.
- Trial name
- RAPIDIMPROVE (NCT07598799)
- Testing
- High-dose RL-IPostC, Low-dose RL-IPostC
- Where
- China
- Volunteers
- 448 people
- Sponsor
- Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Advanced Solid Tumors, Malignant Neoplasm
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery.
- Trial name
- NCT06818643
- Testing
- MK-3120
- Where
- 49 sites in United States, Chile and 10 more
- Volunteers
- 270 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer
Opportunistic Breast Cancer Screening Using Non-Contrast Chest CT
The goal of this observational study is to evaluate the feasibility and effectiveness of using non-contrast chest computed tomography scans for opportunistic breast cancer screening, and to further compare its diagnostic…
- Trial name
- OPBCS-CT (NCT07557654)
- Where
- China
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Fudan University
Ulcerative Colitis (UC)
A Study of AC-101 Tablets in Patients With Ulcerative Colitis
This is a Phase Ⅱb, multicenter, randomized, parallel-group, double-blind, placebo-controlled, dose-finding study of AC-101 tablets in patients with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT07755241
- Testing
- AC-101
- Where
- China
- Volunteers
- 153 people
- Sponsor
- Accro Bioscience (Suzhou) Limited
Extensive-stage Small-cell Lung Cancer
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)
This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of BL-B01D1 in combination with tislelizumab versus platinum-based chemotherapy in combination with…
- Trial name
- NCT07502300
- Testing
- BL-B01D1, Tislelizumab, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 562 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Sjögren's Disease
A Phase 2a/b Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Sjögren's Disease
To evaluate efficacy, safety, and tolerability of DDY391 up to 52 weeks in participants with Sjögren's disease (SjD) and to determine the dose response relationship of DDY391 in participants with SjD, to support dose selection…
- Trial name
- NCT07737743
- Testing
- DDY391
- Where
- 25 sites in United States, Australia and 4 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
A Prospective, Phase II, Exploratory Study Protocol of a Chemotherapy Sensitivity-based Culmerciclib Combination Regimen in Neoadjuvant Therapy for HR+/HER2- Breast Cancer.
To explore the efficacy and safety of Culmerciclib combined with chemotherapy as neoadjuvant therapy for HR+/HER2- breast cancer patients who are insensitive to neoadjuvant TAC (docetaxel, doxorubicin, cyclophosphamide)…
- Trial name
- NCT07900516
- Testing
- Kumoxili, Docetaxel, Epirubicin
- Where
- China
- Volunteers
- 48 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Atrial Fibrillation (Paroxysmal)
Safety and Efficacy of Conscious Sedation Versus General Anesthesia in Pulsed-Field Ablation for Paroxysmal Atrial Fibrillation
The goal of this clinical trial is to compare the safety and efficacy of conscious sedation and general anesthesia in patients with paroxysmal atrial fibrillation undergoing their first pulsed-field ablation (PFA) procedure.
- Trial name
- SEDATE-PFA (NCT07541339)
- Testing
- conscious sedation, General Anesthesia (control group)
- Where
- China
- Volunteers
- 224 people
- Sponsor
- Beijing Anzhen Hospital
Acute Thoraco-Abdominal Emergency Lesions
Vision-Language-Based Large-Scale Model for Emergency Screening
This is a single-center, prospective, stratified 1:1 parallel-group randomized superiority diagnostic trial at The First Hospital of Jilin University.
- Trial name
- NCT07899931
- Testing
- powER vision-language large-model assisted CT reading, Conventional CT reading without AI assistance
- Where
- China
- Volunteers
- 640 people
- Sponsor
- The First Hospital of Jilin University
Knee Osteoarthritis, Replacement, Knee
Exploration of Appropriate BIS Range and Propofol Effect-site Concentration During Total Intravenous Anesthesia With Concomitant Adjuvants.
The goal of this clinical trial is to determine the appropriate Bispectral Index (BIS) range and propofol effect-site concentration required to maintain adequate anesthesia depth during total intravenous anesthesia (TIVA)…
- Conditions
- Knee Osteoarthritis, Replacement, Knee, Elective Surgical Patients, ASA Class I/II Patients
- Trial name
- NCT07736352
- Testing
- Propofol + Remifentanil +Midazolam, Propofol + Remifentanil + Dexmedetomidine, Propofol + Remifentanil + Esketamine
- Where
- China
- Volunteers
- 100 people
- Sponsor
- China-Japan Friendship Hospital
Neurofibromatosis Type 2, NF2
Selumetinib for NF2-Related Schwannomatosis
The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children…
- Conditions
- Neurofibromatosis Type 2, NF2, NF2-related Schwannomatosis, Meningioma
- Trial name
- ASSIST (NCT07707947)
- Testing
- Selumetinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Advanced Solid Tumor
Study SC-101 in Subjects With Advanced Malignancies
This study will evaluate the safety, pharmacokinetics, and anti-cancer efficacy of SC-101 in subjects with advanced or metastatic solid tumors.
- Trial name
- NCT06220838
- Testing
- SC-101
- Where
- 5 sites in China
- Volunteers
- 100 people
- Sponsor
- Tianjin ConjuStar Biologics Co., Ltd.
Heart Failure Due to Coronary Artery Disease
Efficacy of Lipoic Acid on Chronic Ischemic Heart Failure Patients
Chronic heart failure is a clinical condition caused by structural heart disease and is characterized by reduced pumping function, fluid retention, and abnormal activation of neurohormonal systems.
- Trial name
- NCT07725484
- Testing
- Alpha-Lipoic Acid (ALA)
- Where
- 23 sites in China
- Volunteers
- 1,188 people
- Sponsor
- Shanghai Zhongshan Hospital
Systemic Lupus Erythematosus
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 helps people with SLE.
- Trial name
- NCT07409181
- Testing
- BI 3000202
- Where
- 139 sites in United States, Argentina and 19 more
- Volunteers
- 405 people
- Sponsor
- Boehringer Ingelheim